BackEupraxia Pharmaceuticals Overview

Eupraxia Pharmaceuticals Long Term Debt

Eupraxia Pharmaceuticals's long-term debt is $1.8M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.81M

Peer average

Loading

Eupraxia Pharmaceuticals Long Term Debt History

Loading

Eupraxia Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Eupraxia Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eupraxia Pharmaceuticals (EPRX) FAQ

Eupraxia Pharmaceuticals (EPRX) currently reports a long-term debt of $1.8M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Eupraxia Pharmaceuticals's long-term debt history and peer comparisons.

Eupraxia Pharmaceuticals's long-term debt changed from $0 to $1.8M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eupraxia Pharmaceuticals reported $1.8M in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eupraxia Pharmaceuticals, and consider following EPRX for alerts when major investors trade the stock.

Eupraxia Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $1.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPRX with unrelated industries.